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A B S T R A C T
Hydrogen sulfide (H2S) has emerged as an important physiological and pathophysiological signaling molecule in
the cardiovascular system influencing vascular tone, cytoprotective responses, redox reactions, vascular adap-
tation, and mitochondrial respiration. However, bioavailable levels of H2S in its various biochemical metabolite
forms during clinical cardiovascular disease remain poorly understood. We performed a case-controlled study to
quantify and compare the bioavailability of various biochemical forms of H2S in patients with and without
cardiovascular disease (CVD). In our study, we used the reverse-phase high performance liquid chromatography
monobromobimane assay to analytically measure bioavailable pools of H2S. Single nucleotide polymorphisms
(SNPs) were also identified using DNA Pyrosequencing. We found that plasma acid labile sulfide levels were
significantly reduced in Caucasian females with CVD compared with those without the disease. Conversely,
plasma bound sulfane sulfur levels were significantly reduced in Caucasian males with CVD compared with those
without the disease. Surprisingly, gender differences of H2S bioavailability were not observed in African
Americans, although H2S bioavailability was significantly lower overall in this ethnic group compared to
Caucasians. We also performed SNP analysis of H2S synthesizing enzymes and found a significant increase in
cystathionine gamma-lyase (CTH) 1364 G-T allele frequency in patients with CVD compared to controls. Lastly,
plasma H2S bioavailability was found to be predictive for cardiovascular disease in Caucasian subjects as de-
termined by receiver operator characteristic analysis. These findings reveal that plasma H2S bioavailability could
be considered a biomarker for CVD in an ethnic and gender manner. Cystathionine gamma-lyase 1346 G-T SNP
might also contribute to the risk of cardiovascular disease development.
1. Introduction
With recognition and definition of physiologic effects of nitric oxide,
there has been increasing interest in the biological activity of the
“other” gaseous signaling molecules, namely hydrogen sulfide (H2S)
and carbon monoxide (CO). H2S is produced endogenously via enzymes
of the transsulfuration pathway including cystathionine β-synthase
(CBS) and cystathionine γ-lyase (CGL, CTH or CSE), as well as the mi-
tochondrial enzyme 3-mercaptopyruvate sulfurtransferase (MST). H2S
may also be generated through a non-enzymatic process from glucose
(via glycolysis, NADPH oxidase), glutathione (direct reduction), in-
organic and organic polysulfides (present in foods) or through
elemental sulfur (direct reduction) [1,2]. Alteration of H2S bioavail-
ability and metabolism through many of these pathways are known to
influence cardiovascular function and health in experimental models
[3]. Unfortunately, the relationship of H2S bioavailability with clinical
cardiovascular disease conditions remains poorly defined [4,5].
Atherosclerotic cardiovascular disease is still the most common and
costly cause of death in the United States and much of the world [6,7].
Chronic vascular inflammation and sub-endothelial accumulation of
foam cells stimulate occlusion and stenosis of blood vessels, which is a
common culprit underlying peripheral and coronary arterial disease
[8]. Studies have reported that metabolic dysfunction involving re-
duced production of cellular H2S may be a critical factor in the
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progression of experimental cardiovascular disease [2]. Endogenous
H2S production is significantly reduced in the CTH (CSE) knockout
mouse model, which is associated with impaired endothelial vasodila-
tion and hypertension, increased production of reactive oxygen species,
increased vascular inflammatory responses, and enhanced vascular
atherosclerosis [9]. Further, H2S therapy using sulfide donors has been
reported to diminish vascular inflammatory responses, decrease re-
active oxygen species, and promote ischemic vascular remodeling/an-
giogenesis involving increased NO production [1].
Congruent with the current literature, H2S exists in different bio-
chemical forms, including free or unbound sulfide (S2-, HS- or H2S), acid
labile sulfide (ALS), and bound sulfane sulfur (BSS) [10–12]. These
sulfur pools are crucial in regulating the total amount of bioavailable
sulfide. ALS exists primarily in the form of iron–sulfur (Fe–S) complexes
that modulate cellular functions including mitochondrial respiration
and cytoplasmic redox reactions. BSS includes various compounds such
as persulfides, polysulfides, thiosulfate, polythionates, thiosulfonates,
bisorganylpolysulfanes or monoarylthiosulfonates, elemental sulfur,
and many others. BSS compounds such as per/polysulfides can release
H2S under reducing conditions suggesting that the cellular redox state is
important for regulating its bioavailability. The precise chemistry
through which these different biological pools of H2S interact to affect
their pathophysiological functions is an area of active research. How-
ever, differences in bioavailability of these biochemical pools of sulfide
remain largely unknown in part due to difficulties in measuring them.
Overall, the sulfide field has been limited by controversies related to
measurements of H2S in various biological systems. Our lab has es-
tablished and validated analytical chemistry methods to accurately
detect and quantify discrete H2S pools using a monobromobimane
(MBB) assay coupled with reverse-phase high performance liquid
chromatography (RP-HPLC), which was verified by electrospray ioni-
zation mass spectrometry [11,13,14].
In this study, we report findings of a clinical case-control study to
accurately measure the amounts of different sulfide biochemical pools,
namely ALS (with free sulfide combined), BSS, and total sulfide in
subjects with coronary artery disease (CAD) or peripheral artery disease
(PAD) compared to those without disease (controls). By combining
clinically validated diagnoses with thoroughly established analytical
chemistry techniques, these data provide important new insight re-
garding variations in bioavailability of sulfide biochemical pools and
their association with cardiovascular disease states.
2. Materials & methods
2.1. Study design
This was a case-control study approved by the Institutional Review
Board (IRB) of Louisiana State University Health Sciences Center at
Shreveport (LSUHSC-S). Patients over 40 years of age who presented to
the cardiac catheterization laboratory at LSUHSC-S for coronary or
peripheral angiography were recruited for this study. Healthy, age-
matched volunteers were also enrolled as controls. Each patient's ankle
brachial index (ABI) was measured as we previously described [6] and
each patient was also administered the San Diego Claudication Ques-
tionnaire prior to angiography. Following exclusion criteria, the total
study population consisted of 278 Caucasian and African American
(AA) subjects categorized into three basic subgroups (Fig. 1):
Healthy controls: healthy volunteers and patients with less than
50% occlusion of all major coronary or peripheral arteries and a
normal ABI (1.4>ABI>0.9).
Coronary arterial disease (CAD): patients with greater than or equal
to 50% occlusion of any major coronary artery and a normal ABI
(1.4>ABI>0.9).
Peripheral arterial disease (PAD): patients with greater than 50%
occlusion of a major limb artery and/or an abnormal ABI
(ABI< 0.9).
2.2. Exclusion criteria
Volunteers who were excluded from this study were those who
could not provide informed consent, were participating in another
clinical trial involving experimental therapeutics, or were pregnant or
nursing. Patients with ST elevated myocardial infarction or cardiogenic
shock were not included to avoid interference with time-sensitive re-
vascularization and confusion of pathophysiological events. Additional
exclusion criteria included patients with an ABI> 1.4 (due to non-
compressible arteries) or patients with Buerger's disease (non-athero-
sclerotic PAD).
2.3. History and blood collection
Patients were interviewed and medical record data were collected
for analysis of typical cardiovascular risk factors such as hypertension,
diabetes, obesity, tobacco use, and dyslipidemia. Blood samples were
collected from already-established catheterization into 6mL BD vacu-
tainer tubes with lithium heparin. Samples were transported to the lab
within 15min on ice and were centrifuged at 1500 RCF for 4min at
4 °C.
2.4. Measurement of biological pools of H2S
Plasma samples were analyzed for free sulfide, ALS, BSS, and total
sulfide levels as we have previously reported [11,13]. Free sulfide was
measured using the MBB method as previously reported [11]. For de-
tection of ALS and BSS, 50 μl of plasma was added separately into two
sets of 4mL BD vacutainer tubes. Four hundred fifty microliters of
100mM phosphate buffer (pH 2.6, 0.1mM DTPA) was added to one
tube [acid labile reaction] and 450 μl of 100mM phosphate buffer (pH
2.6, 0.1mM DTPA) plus 1mM TCEP was added to the second tube
[total sulfide reaction]. Following a 30-min incubation on a nutator, the
reaction liquid was removed and sulfide gas subsequently trapped by
adding 500 μl of 100mM Tris-HCl buffer (pH 9.5, 0.1mM DTPA) into
the BD vacutainer tube and incubated again for 30min on a nutator
mixer. The trapping solutions were removed and sulfide levels mea-
sured using the MBB method as we have previously reported [13].
Determination of ALS was made by reacting plasma samples with acidic
phosphate buffer alone and subsequent trapping of evolved sulfide.
Measurement of BSS was determined by subtracting the acid labile
value from the total sulfide protocol containing TCEP reductant treat-
ment under acidic conditions. Total sulfide levels were directly ob-
tained from the total sulfide reaction.
2.5. MBB assay and RP-HPLC detection
Thirty microliters of reaction buffer with trapped sulfide was
transferred to a PCR tube and mixed with 70 μl of H2S stabilization
buffer (100mM Tris-HCl, 0.1mM DTPA, pH 9.5) and 50 μl MBB solu-
tion (10mM). Samples were then incubated in a hypoxic chamber (1%
O2) for 30min at room temperature. The reaction was stopped by
adding 50 μl of 200mM sulfosalicylic acid, followed by centrifugation
at 12,000 rpm for 10min at 4 °C. One hundred microliters of super-
natant was collected for RP-HPLC. Ten microliters of the supernatant
was transferred into the RP-HPLC system with an Agilent Eclipse XDB-
C18 column (5 µm, 80 Å, 4.6 mm × 250mm) equilibrated with 15%
CH3CN in water containing 0.1% (v/v) TFA for fluorescence detection
(excitation: 390 nm; emission: 475 nm).
MBB and sulfide-dibimane were separated using the gradient of two
mobile phases: (A) water containing 0.1% (v/v) TFA and (B) 99.9%
CH3CN, 0.1% (v/v) TFA at a flow rate of 0.6 mL/min. Retention time
for sulfide-dibimane is 16.5 min and MBB is 17.6 min. The amount of
H2S was measured from linear plots of the HPLC peak areas of sulfide-
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Fig. 1. Study organization flow chart. A total of 324 patients
were used for analysis, including 209 males and 115 females. This
subject population was subsequently diagnosed with or without
CAD or PAD after cardiac catheterization. CAD indicates coronary
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Fig. 2. Plasma sulfide bioavailability by ethnicity. Total sulfide, acid labile pools, and bound sulfide in total subject populations (combined), Caucasian and African American subjects
respectively with any form of CVD. CVD indicates cardiovascular disease. Control Caucasian vs African Americans ### p=0.0001; #p=0.0028; ##p=0.0326.
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dibimane versus standard concentration of sulfide solution.
2.6. Statistical analysis
Levels of ALS, BSS and total H2S in the three subgroups were first
assessed by group means and standard deviations with subsequent
pairwise comparison using analysis of variance (ANOVA). Multiple
linear regression analysis was conducted to delineate the relationship
between sulfide pools and the dependent variables including race,
gender, diagnosis of CAD and PAD, and cardiovascular risk factors.
Receiver-operating characteristic analysis (ROC) was conducted to as-
sess the predictive accuracy in correlating sulfide levels with CAD or
PAD diagnosis. Cutoff values for positive classification were included in
the curve, with a nonparametric distribution assumption and a con-
fidence level of 95%. All statistical analyses were performed using
GraphPad Prism 5.0.
3. Results
3.1. Sulfide bioavailability associated with cardiovascular disease
Plasma sulfide bioavailability was initially compared between con-
trol subjects and patients with any form of cardiovascular disease (any
CVD). Fig. 2 illustrates that total, acid labile, and bound sulfide were all
significantly reduced in patients with any CVD. Stratifying subjects
based on ethnicity revealed a significant reduction in plasma total, ALS,
and BSS in CVD patients compared to controls among Caucasian
subjects, which was not observed in African Americans. However,
comparison of control cohorts of African Americans to Caucasians re-
vealed a significant reduction in plasma total sulfide (1.015 vs 1.389)
and BSS levels (0.431 vs 0.266) in the African Americans.
3.2. Sulfide bioavailability as a function of gender
The association of plasma sulfide levels was compared between the
subject population with and without CVD based on gender. Fig. 3 il-
lustrates that women with any CVD display a significant reduction in
total sulfide and ALS levels. There were no significant differences in BSS
levels. Stratifying by race and gender further revealed that Caucasian
female CVD patients had significantly reduced total sulfide and ALS
levels compared to African American female CVD patients. Fig. 4 de-
monstrates that all males with any CVD had significantly reduced
plasma total and BSS levels. Segregation by race and gender again re-
vealed that plasma total and BSS levels were significantly reduced only
in Caucasian males with CVD. Together, these data reveal discrete novel
differences in plasma sulfide metabolites during cardiovascular disease
between males and females.
3.3. Sulfide bioavailability as a function of coronary or peripheral artery
disease
Plasma sulfide metabolite levels were next analyzed based on the
diagnosis of either CAD or PAD. Importantly, a majority of patients
(> 85%) diagnosed with PAD were also diagnosed with CAD indicating
Fig. 3. Plasma sulfide pools in Women by ethnicity. Total sulfide, acid labile pools, and bound sulfide levels of Plasma have been displayed in female subjects with and without any
CVD. CVD indicates cardiovascular disease. Control Caucasian vs African Americans ###p=0.0031; #p=0.06555.
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broad CVD, which has been previously reported [4,15]. Stratifying CVD
subjects diagnosed as PAD or CAD revealed a significant reduction in
plasma total and BSS levels (Fig. 5). Plasma total and BSS levels in
Caucasian subjects with either CAD or PAD were significantly lower
compared to controls, while levels of ALS were not significantly re-
duced. African American subjects with PAD had reduced BSS compared
to controls. Conversely, BSS levels were significantly elevated in
African Americans with CAD compared to PAD subjects but not that of
controls. Together, these data reveal that plasma sulfide bioavailability
is predominantly reduced in Caucasian subjects with either CAD or
PAD. A comparison of different ethnicities between control cohorts
revealed significantly reduced base levels of plasma sulfide in African
Americans to Caucasians.
3.4. Sulfide as an indicator of cardiovascular disease
Based on the observed differences in plasma sulfide measurements
between CVD patients and controls in a gender and ethnic manner, we
next performed receiver operator analysis to determine the accuracy of
reduced sulfide levels as an indicator for CVD. Caucasian male and
female plasma total sulfide levels were analyzed separately revealing an
area under the curve (AUC) of 0.7591 (p = 0.0005) for males and
0.7318 (p = 0.005) for females (Figs. 6A and 6B). Having observed
significant gender differences of Caucasian plasma sulfide metabolite
pools, these data were further analyzed using plasma ALS in females
and plasma BSS in males. Fig. 6C shows the female Caucasian ALS AUC
was 0.6879 (p=0.022), whereas the male Caucasian BSS was 0.7142
(p=0.0042) (Fig. 6D). Lastly, plasma total sulfide levels were analyzed
based on ethnicity and found to be a statistically significant indicator of
CVD in Caucasian patients regardless of gender, with an AUC of 0.76
(p< 0.0001) (Fig. 6E). However, total sulfide levels were not identified
as an indicator for CVD in African American patients (Fig. 6F).
Linear regression analysis was further utilized to determine re-
lationships between sulfide biochemical metabolite pools with various
dependent variables related to cardiovascular disease including age,
sex, diagnosis, BMI, tobacco use, and dyslipidemia based on subject
demographics (Table 1). Regression analysis of CVD risk factors for all
subjects revealed significant associations with ethnicity, diagnosis, and
gender. Importantly, in both Caucasian and African American subjects,
females were associated with higher levels of total sulfide, ALS, and BSS
levels than males (Tables 2, 3). The most consistent linear regression
trends were seen in Caucasian subjects with cardiovascular disease
(Table 2). Among this subgroup, total sulfide, ALS, and BSS levels were
significant and most strongly associated with a diagnosis of CVD, along
with other significant yet weaker associations of gender, hypertension,
and smoking status. While a weak association with diagnosis was also
observed in African Americans, these results were not as significant
compared to Caucasians (Tables 3, 4).
3.5. Single Nucleotide Polymorphisms (SNPs)
A study by Wang et al. suggests that genetic variation in cy-
stathionine gamma-lyase (CTH) is associated with elevated plasma
homocysteine levels [16]. To further identify any such associations with
Fig. 4. Plasma sulfide pools in Men by ethnicity. Total sulfide, acid labile pools, and bound sulfide levels of Plasma have been displayed in male subjects with and without any CVD.
CVD indicates cardiovascular disease. Control Caucasian vs African Americans ###p=0.0338; #p=0.03085.p = .0338; #p = .03085.
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CVD, we screened a subset of our patient population for SNPs in three
enzymes related to H2S and NO metabolism to determine if variations in
allele frequencies existed between CVD patients and controls. After
screening for 7 SNPs in the CTH, CBS, and eNOS (endothelial nitric
oxide synthase) genes, we identified 2 polymorphisms with consider-
able variation in allele frequencies among our patient population: 1
SNP in the NOS3 gene and 1 in the CTH gene.
The CTH 1364 G>T SNP (Rs1021737) involves a point mutation in
exon 12 of the CTH gene that was previously identified in patients with
hyperhomocysteinemia [16,17]. In our patient population, the mutant
1364 T allele frequency was higher in patients with CVD (0.265) and
either CAD or PAD (0.256 or 0.273) compared to controls (0.107)
(Table 5). We also identified an SNP in exon 8 of the eNOS gene
(894 G>T) with considerable allelic variation among our patient po-
pulation. The 894 G>T mutation (Rs1799983) has been previously
identified in several studies among patients with hypertension, cere-
brovascular disease, and CAD [18–20]. The allele frequency of this
mutation was highest in patients with CAD compared to controls (0.273
vs. 0.143, respectively; Table 5). These data suggest that the CTH
1364 G>T SNP is a potential risk factor with increasing mutation al-
lele frequency with CVD including PAD and CAD, whereas eNOS
894 G>T was associated with increased risk of CAD.
4. Discussion
Hydrogen sulfide metabolism and its bioavailability have been
associated with vascular dysfunction and disease, which has been de-
monstrated in several experimental models [5,9,21]. However, the re-
lationship between sulfide bioavailability and clinically validated car-
diovascular disease remains poorly understood due to lack of a reliable
and sensitive analytical measurement of sulfide in its various bio-
chemical forms coupled with well defined, clinically validated subjects.
For the first time, our study indicates an association of polysulfide to
any form of vascular disease. We have reported the levels of total, acid
labile and bound sulfane sulfide in plasma samples from clinical sub-
jects of vascular disease using validated analytical chemistry metho-
dology that others and we have extensively characterized [10–14].
Importantly, we found that subjects with CVD have lower bound and
total sulfide metabolites compared to control subjects, which were
observed in an ethnic and gender specific manner. As we have pre-
viously reported, the relevance of different sulfide biochemical forms
including ALS and BSS represent biochemical sulfide reservoirs. These
sulfide equivalents may be important under various pathophysiological
conditions, which might be inter-convertible depending on pH and
redox balance [1,2]. Thus, the ALS and BSS pools are postulated to be a
‘reversible sulfide sink’ as free H2S is ephemeral, making it difficult to
account for its prolonged physiological actions.
The biological effects of H2S are increasingly attributed to per/
polysulfides that are produced endogenously in many cells and tissues
of mammalian origin. These per/polysulfides can reversibly generate
H2S by their degradation, which could play critical physiological roles
[22–24]. Additionally, conversion of a thiol to the corresponding
Fig. 5. Sulfide bioavailability in CAD and PAD subjects. Plasma total, acid labile and bound sulfane sulfide pools in a combined or total subject population, Caucasian and African
American subjects with either CAD or PAD. CAD indicates Coronary arterial disease; PAD, Peripheral arterial disease. Control Caucasian vs African Americans ###p=0.0001;
#p=0.0028; ##p=0.0326.
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hydropersulfide can result in a change of catalytic activity within the
protein. The physiological significance of BSS is not completely un-
derstood but has recently been appreciated beyond being a storage form
of sulfide. Persulfides such as alkyl hydropersulfides may be generated
via H2S-independent mechanisms and can have a greater biological
activity [22,25]. As mentioned earlier, the literature suggests that BSS
includes compounds such as per/polysulfides. However, the role of BSS
in clinical complications such as cardiovascular disease has not been
identified. Here, we observed lower levels of BSS in subjects with
vascular disease and those with major cardiovascular risk factors. This
could be either a manifestation of the disease state itself or a “com-
pensatory mechanism” that enables movement of sulfide to more
bioavailable pools (H2S/S2-/HS-) that exert beneficial effects including
anti-oxidation, vasodilation or angiogenesis. In support of the latter
theory, BSS has been shown to release H2S in reducing conditions [2].
This BSS-derived sulfide could then have biological implications that
are known to be associated with H2S.
BSS also appears to be a major product of the cysteine
Fig. 6. Receiver-operating characteristic analysis
(ROC) in subjects with CVD. ROC curves with area
under the curve of Caucasian population A. total
sulfide levels in females B. total sulfide levels in
males C. Acid labile pools in females D. Bound sul-
fane sulfur in males and E. total sulfide. F. Total





Age 54.44± 8.27 58.73± 7.94 57.83±8.86
Total AA Cauc Total AA Cauc Total AA Cauc
89 50 39 76 40 36 113 44 69
Males 45(51%) 26 19 60(78%) 35 25 66(58%) 19 47
Females 44(40%) 24 20 16(22%) 5 11 47(42%) 25 22
DM 27(30%) 19 8 29(38%) 14 15 48(42%) 26 22
HTN 70(78%) 47 23 62(81%) 39 33 104(92%) 61 43
Smokers 29(32%) 16 13 37(49%) 20 17 38(34%) 10 28
BMI>30 43(48%) 31 12 25(32%) 12 13 64(56%) 23 31
AA = African American; Cauc = Caucasian; PAD = Peripheral Arterial Disease; CAD = Coronary Artery Disease.
DM = Diabetes Mellitus; HTN = Hypertension; BMI = Body Mass Index.
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aminotransferase and MST pathway and has been proposed to be the
major pathway for sulfide signaling in the brain [26,27]. H2S can be
liberated from MST – BSS by the ubiquitous reductant, thioredoxin and
by dihydrolipoic acid, both present in cells. Additionally, CTH and CBS
can also generate BSS in tissues using thiol substrates including
homocysteine, cysteine, cystathionine, and cystine, with cysteine hy-
dropersulfide (Cys-SSH) as an intermediate [22]. A very recent study
has demonstrated that cysteine tRNA synthase (CARS), which is in-
volved in cysteine metabolism and aminoacyl-tRNA synthesis is another
major source of cysteinepersulfide in vivo [28]. Interestingly, the
kinetics of these enzymes vary with conditions such as oxidative stress,
that influence changes in the generation of reactive persulfide species
[29].
A previous study from our lab reported elevated levels of plasma
free H2S in subjects with vascular disease [4]. Supplementary table 1
shows that free sulfide levels were not significantly different within this
current cohort of subjects. An explanation for this observation may be
due to the inclusion of subjects with acute coronary syndromes (ACS) or
critical limb ischemia (CLI) in our previous study [4], which are not
included here. Importantly, alteration of free H2S is known to occur
where hypoxia is an active component of tissue dysfunction and may
contribute to our previous findings [2,9]. Additional studies are
planned to examine the relationship between ACS or CLI and plasma
sulfide metabolites.
It is well known through numerous studies that African American
(AA) subjects are more predisposed to vascular disease [30–33]. In-
terestingly, we observed low levels BSS in male AA subjects. Specifi-
cally, AA subjects with PAD had reduced BSS compared to controls.
Low BSS could potentially be a marker for increased risk for vascular
disease in AA subjects. Conversely, lower BSS levels in Caucasian sub-
jects with vascular disease could indicate that BSS has a protective ef-
fect in Caucasians that is lost in vascular disease. These observations
suggest that BSS may serve as a dynamic sulfide metabolite influencing
vascular disease, which requires further study.
An alternative hypothesis is that reduced sulfide metabolites re-
present deficient endogenous production of sulfide due to the devel-
opment of CVD itself. Low sulfide levels have been shown to accelerate
experimental atherosclerosis, supporting the notion that low BSS is a
manifestation of the diseased vasculature. In a study by Mani et al., it
was shown that decreased endogenous production of H2S led to ac-
celerated atherosclerosis [34]. In another study, Zavaczki et al. has
shown that hydrogen sulfide inhibits the calcification and osteoblastic
differentiation of vascular smooth muscle cells and suggested that low
H2S could promote vascular calcification seen in atherosclerosis [35].
Several studies demonstrate an increase in production of reactive
oxygen species (ROS) in atherosclerosis [36]. BSS is known to be an
antioxidant and its low levels could be a manifestation of its utilization
and consumption in redox reactions. This may explain the low BSS le-
vels as well as the protective effect of sulfide. That low H2S is a man-
ifestation of the disease state is also supported by our observation of
low BSS under CVD. However, future studies are required to better
understand specific pathophysiological relationships between sulfide
bioavailability and vascular disease.
In conjunction with these observations, ethnicity and gender were
found to be significant variables associated with total sulfide, ALS, and
BSS with a diagnosis of CVD. Regression analyses show a significant
reduction in plasma sulfide levels with onset of CVD in Caucasian pa-
tients. Notably, a significant association is observed with total sulfide,
ALS, and BSS levels in females in comparison to the males in both
Caucasians and African Americans. Additionally, SNP analysis of H2S
synthesis enzymes revealed that polymorphisms in CTH (but not CBS)
Table 2
Regression analysis of CVD risk factors for all subjects.
Dependent
Variable
Total Sulfide Acid Labile Sulfide Bound Sulfide
β1 p value β1 p value β1 p value
Age −0.911 0.363 −0.743 0.572 −2.684 0.162
Sex 0.329 0.001 0.270 0.001 0.414 0.001
Race −0.104 0.075 −0.195 0.006 −0.074 0.507
Diagnosis −0.661 0.001 −0.835 0.001 −0.930 0.004
BMI>30 1.487 0.136 1.460 0.272 2.322 0.215
Smoking Status −0.222 0.015 −0.234 0.053 −0.354 0.044
Dyslipidemia −0.013 0.828 −0.017 0.823 −0.032 0.765
Hypertension −0.056 0.088 −0.070 0.106 −0.087 0.166
Table 3
Regression analysis of CVD risk factors for Caucasian subjects.
Dependent
Variable
Total Sulfide Acid Labile Sulfide Bound Sulfide
β1 p value β1 p value β1 p value
Age −0.057 0.965 0.413 0.804 −2.671 0.259
Sex 0.391 0.001 0.251 0.005 0.442 0.001
Diagnosis −1.218 0.001 −1.327 0.001 −1.780 0.001
BMI>30 3.946 0.0141 5.342 0.010 2.064 0.459
Smoking Status −0.310 0.0120 −0.308 0.054 −0.482 0.032
Dyslipidemia −0.111 0.158 −0.109 0.357 −0.225 0.113
Hypertension −0.127 0.0246 −0.150 0.043 −0.175 0.091
Table 4
Regression analysis of CVD risk factors for African American subjects.
Dependent
Variable
Total Sulfide Acid Labile Sulfide Bound Sulfide
β1 p value β1 p value β1 p value
Age −1.922 0.217 −2.323 0.274 −2.748 0.382
Sex 0.276 0.001 0.338 0.003 0.383 0.023
Diagnosis −0.164 0.503 −0.386 0.247 0.178 0.720
BMI>30 −0.222 0.861 −1.596 0.354 2.591 0.309
Smoking Status −0.159 0.247 −0.200 0.284 −0.206 0.458
Dyslipidemia 0.0850 0.303 0.060 0.592 0.2143 0.198
Hypertension 0.0408 0.165 0.057 0.157 0.0421 0.478
Table 5
Mutant allele frequencies of CTH, CBS, and NOS3 single-nucleotide polymorphisms. CTH: Cystathionine γ-lyase; CBS: cystathionine β-synthase; NOS3: endothelial NO synthase; PAD:
Peripheral artery disease; CAD: Coronary Artery Disease; CVD: Cardiovascular Disease (PAD and/or CAD); N/A: not applicable – mutant allele not detected within cohort.
Gene symbol Chromosome Polymorphism dbSNP Mutant Allele Frequency
Controls PAD CAD CVD
N = 28 N = 41 N = 44 N = 85
CTH 1p31 1364 G>T Rs1021737 0.107 0.256 0.273 0.265
CTH 1p31 356 C>T Rs28941785 N/A N/A 0.023 0.011
CTH 1p31 874 C>G Rs28941786 N/A N/A N/A N/A
CBS 21q22 833 T>CT Rs5742905 0.035 0.02 N/A 0.021
CBS 21q22 1058 C> Rs121964972 N/A N/A 0.012 0.006
NOS3 7q36 894 G>T Rs1799983 0.143 0.159 0.273 0.224
NOS3 7q36 − 786 T>C Rs2070744 0.232 0.159 0.318 0.241
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are a potential risk factor for vascular disease development. It is known
that CTH is a key enzyme for production of H2S in the cardiovascular
system. Others and we have previously reported that endogenous H2S
production is significantly reduced in CTH (CSE) deficient mice, which
could translate to clinical implications for the development of vascular
disease [9,34]. Deficiency in bioavailable sulfide may be associated
with polymorphic variants of CTH as a previous report revealed an
association of CTH SNP with increased serum homocysteine levels [16].
Our findings regarding CTH 1364 G-T allele frequency in patients with
CVD advances the hypothesis that a CTH SNP 403Ser to 403Ile is as-
sociated with decreased sulfide bioavailability and has clinical asso-
ciations in patients with chronic vascular disease conditions. However,
future studies are needed to identify how this missense mutation alters
enzyme function in vivo compared to a previous enzymatic study that
did not find alterations in CTH pyridoxal-5’-phosphate cofactor content
or steady state kinetic properties [36].
4.1. Study limitations
Our study is not without limitations. All subjects were included who
presented for cardiac or peripheral arterial catheterization, and for
whom an accurate diagnosis could be made. In general, subjects who
were scheduled for cardiac catheterization, even if they do not have the
clinically defined disease, are usually those with greater cardiovascular
risk factors. In an attempt to mitigate this limitation, normal volunteers
with less than 2 cardiovascular risk factors and no history of cardio-
vascular disease were also included in the control group but not sub-
jected to catheterization, as doing this procedure in healthy subjects is
not justifiable (for obvious reasons). A second limitation is the fact that
ABI was used to detect PAD. Even though ABI is a good screening tool
its utility in diagnosing PAD accurately may be limiting, in that a few
patients who have PAD could have been missed. Some of our patients
had indeterminate ABIs, which would require further clinical workup
with an ultrasound modality to rule out PAD if there is high clinical
suspicion, which was not done in this study. A third limitation is that
we could not assess the role of hypertension as an important risk factor
for CVD. This is due to the fact that more than 90% of patients
scheduled for cardiac catheterization had hypertension and we were
unable to establish a meaningful “normotensive” group. A final lim-
itation was the smaller sample size associated with the genetic poly-
morphism study. However, this study produced convincing preliminary
evidence that mutations in CTH and eNOS genes are higher among
patients with CVD, with these initial findings substantiating the need
for further investigation. These limitations aside, our findings reveal
that reduced sulfide metabolite bioavailability is significantly asso-
ciated with cardiovascular disease along with increased single nucleo-
tide polymorphisms of CTH. Lastly, additional studies distinguishing
specific inorganic and organic per/polysulfides such as cysteine or
glutathione-related sulfur species in CVD are needed to better under-
stand the relationship of these metabolites with CVD.
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